Ocugen, Inc. Profile Avatar - Palmy Investing

Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function…

Biotechnology
US, Malvern [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Ocugen, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of OCGN's Analysis
CIK: 1372299 CUSIP: 67577C105 ISIN: US67577C1053 LEI: - UEI: -
Secondary Listings
OCGN has no secondary listings inside our databases.